Drug search by name

Signifor (Pasireotide Extended-Release Injection) and Adrenal insufficiency

Result of checking the interaction of drug Signifor (Pasireotide Extended-Release Injection) and disease Adrenal insufficiency for safety when used together.

Check result:

Signifor (Pasireotide Extended-Release Injection) <> Adrenal insufficiency

Relevance: 23.07.2019 Reviewer: Shkutko P.M., M.D., in

When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.

Consumer:

Treatment with somatostatin analogs may suppress the pituitary hormones other than GH/IGF-1. It is recommended to monitor pituitary function prior to initiation of therapy and periodically during treatment, as clinically appropriate. Patients should be monitored for and instructed on the signs and symptoms of adrenal insufficiency during therapy. If adrenal insufficiency is suspected it should be confirmed and treated per standard of care with exogenous glucocorticoids at replacement doses.

Signifor (Pasireotide Extended-Release Injection)

Generic Name: pasireotide

Brand Name: Signifor, Signifor LAR

Synonyms: Signifor, Signifor Injection

What is Signifor (Pasireotide Extended-Release Injection)?